125742 S56 M1 cover

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

2

Document text

Pfizer Global Regulatory Affairs
Pfizer Inc.
400 Arcola Road Collegeville, PA 19426
Global Product Developm ent
17 August 2021
Marion Gruber, Ph.D.
Director
Office of Vaccines Research and Review 
Food and Drug Administration
Center for Bi ologics Evaluation and Research
Document Control Center
10903 New Hampshire Avenue
WO71, G112
Silver Spring, MD 20993 -0002THIS DOCUMENT CONTAINS 
CONFIDENTIAL AND/OR TRADE S ECRET 
INFORMATION THAT IS DISCLOSED ONLY 
IN CONNECTION WITH THE LICENSING 
AND/OR REGISTRATION OF PRODUCTS FOR 
PFIZER INC OR ITS AFFILIATED 
COMPANIES.  THIS DOCUMENT SHOULD 
NOT BE DISCLOSED OR USED, IN WHOLE OR 
IN PART, FOR ANY OTHER PURPOSE 
WITHOUT THE PRIOR WRITTEN CONSENT 
OF PFIZER INC.
Re:BLA 125742.0
COVID-19 mRNA Vaccine ( BNT162/PF -07302048 )
Commitment to FDA’s1
3August 2021 Information Request Regarding 
Implementing New Method for Endotoxin
Dear Dr. Gruber,
Reference is made to the Biologics License Application (BLA) submitted 1 8May 2021 for 
the COVID- 19 mRNA Vaccine (BNT162/PF -07302048) developed b y BioNTech and Pfizer
under BB -IND 19736 for the prevention of COVID -19caused by SARS-CoV-2in 
individuals ≥16 years of age.
On 13 August 2021, the Agency  sentan Information Requestfor a new method for testing 
 samples. In addition, on 16 August 2021, the Agency and Pfizer met via 
teleconference to obtain clarity  on the given request.  The requested information and 
commitm entareprovided in Commitment to I mplement an Additional Endotoxin Method on 
 DPin Module 1.11.1.
Should you have any  questions regarding this submission, or require additional information, 
please contact me via phone at 215- 280-5503; via facsimile at 845- 474-3500; or via e -mail at 
[email protected] .
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1149869
Marion Gruber, Ph.D., Director Page 2of 2
BLA125742 17August2021
Pfizer Confidential
Page 2Sincerely,
Elisa Harkins
Global Regulatory  Lead
Global Regulatory Affairs – Vaccines
CC: Ramachandra S. Naik, Ph.D.
CC: Michael Smith, Ph.D.
CC: Laura Gottschalk, Ph .D.
FDA-CBER-2021-5683-1149870